| Ytd | -87.78% | |
| 1y | -74.90% |
| Open | 4.51 | Prev Close | 4.50 | Low | 4.50 | High | 5.37 | Mkt Cap | 230.27M |
| Vol | 3.49M | Avg Vol | 1.10M | EPS | -2.18 | P/E | -2.34 | Forward P/E | -18.18 |
| Beta | 1.33 | Short Ratio | 10.62 | Inst. Own | 100.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 41.67 | 200-d Avg | 40.08 | 1yr Est | 53.20 |
SION News
Sionna Therapeutics NASDAQ: SION said its PreciSION CF Phase 2a proof-of-concept study of SION-719 a
Clinical-stage biopharmaceutical company Sionna Therapeutics Inc. (NASDAQ:SION) announced topline cl
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul
US stocks mixed, Dow Jones down 0.2% midday. Energy shares up 3%, real estate down 1.4%. National En
The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the
Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program
San Diego, California--(Newsfile Corp. - August 10, 2026) - Johnson Fistel, PLLP, a leading stockhol
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m
PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to sta
Top Wall Street analysts changed outlook on top names. Check analyst ratings page for full changes.
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit
